Added to YB: 2025-11-20
Pitch date: 2025-11-19
NVO [neutral]
Novo Nordisk A/S
-0.38%
current return
Author Info
Compound & Fire shares at least one company deep dive every month. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 317.60
Price Target
228.00 (-29%)
Dividend
3.63%
EV/EBITDA
8.96
P/E
13.76
EV/Sales
4.74
Sector
Pharmaceuticals
Category
value
Novo Nordisk ($NVO): A Quality Investing Deep Dive into the GLP-1 Leader's Long-Term Potential and Risks
NVO (short-term pass): Despite quality foundation structure, vertical integration & obesity TAM of 934M growing 7% annually (97% untapped), facing structural market share decline vs Lilly (80%→57% obesity, 56%→52% GLP-1). Compounding headwinds, potential US pricing pressure, patent cliff 2031-32. At 14x forward PE needs 13-15% FCF growth for 10% return. Quality company, insufficient margin of safety.
Read full article (69 min)